Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT
Radiation Induced Change of Liver Function Measured by Uptake of the Galactose Analogue FDGal and PET/CT
Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy. This technique provides volumetric mapping of liver function and it allows quantisation of liver function. The method may be used for selection of patients for stereotactic radiotherapy of liver tumors, for determination of radiation induced liver dysfunction and may be included into the treatment planning process of stereotactic radiotherapy.
Uptake of FDGal
Measuring liver function by PET/CT
Study Arms / Comparison Groups
Description: Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Primary Completion Date
Inclusion Criteria: - liver tumor - referred for stereotactic radiation therapy - age > 18 years Exclusion Criteria: - Impaired kidney function - Pregnancy
18 Years - 85 Years
Accepts Healthy Volunteers
Morten Høyer, MD PhD, ,
University of Aarhus
Danish Cancer Society
Morten Høyer, MD PhD, Principal Investigator, Aarhus University Hospital